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a b s t r a c t
Resistin is an adipokine produced by the white adipocytes and
adipose-derived macrophages, which mediates inflammation and
insulin resistance Huang et al., 1997 and Renehan et al., 2008 Feb.
Here, we provide data on the effect of resistin on epithelial to
mesenchymal transition (EMT) in breast cancer cells in vitro. As
model systems, we used human MCF-7 (low-metastatic) and MDA-
MB-231 (high-metastatic) breast cancer cell lines. To optimize
experimental conditions, we treated the cells with various con-
centrations of resistin (12.5, 25 and 50 ng/ml) for different time
intervals (6 and 24 hours), and measured SOCS3 mRNA expression
by using qRT-PCR analysis. Further, we used qRT-PCR and Western
blot analyses to measure the expression of various epithelial (E-
cadherin, claudin-1) and mesenchymal (SNAIL, SLUG, ZEB1,
TWIST1, fibronectin, and vimentin) markers after resistin
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treatment. This data article is part of a study Avtanski et al., 2019
May, where detailed interpretation and discussion can be found.
© 2019 The Author(s). Published by Elsevier Inc. This is an open
access article under the CC BY license (http://creativecommons.
org/licenses/by/4.0/).
1. Data
1.1. Effect of resistin on suppressor of cytokine signaling 3 (SOCS3) mRNA expression
Resistin is acytokine produced by the white adipose tissue (WAT) that is known to play a major role
in mediating insulin sensitivity of the insulin target tissues [1,2]. Previous research by Steppan et al. [4]
demonstrated that resistin treatment of 3T3-L1 adipocytes (at concentration of 20 ng/ml) markedly
induced the gene expression of suppressor of cytokine signaling 3 (SOCS3). Here, we used SOCS3 as a
control gene to optimize the treatment conditions of human MCF-7 and MDA-MB-231 breast cancer
cells with resistin. Cells were treated with increasing concentrations of human resistin (8.3, 12.5, 25,
and 50 ng/ml) for 6 and 24 hours, and resistin mRNA expression levels were measured by qRT-PCR
analysis. Data were presented as fold-change of resistin treatment vs. non-treated (Control) cells at
6 and 24 hours. Results demonstrated that resistin statistically significant upregulated SOCS3 mRNA
levels in both, MCF-7 and MDA-MB-231 cells, as maximal effect was reached at concentration of 12.5
ng/ml for 6 hours of treatment (Fig. 1 and Table 1).
Specifications table
Subject area Biology
More specific subject area Oncology
Type of data Figures, tables
How data was acquired qRT-PCR: QuantStudio 3, Applied Biosystems
Western blot: MyECL Imager, Thermo Fisher
Statistical analysis: GraphPad Prism software, GraphPad Software, Inc.
Data format Raw and analyzed
Experimental factors MCF-7 andMDA-MB-231 breast cancer cells were treated with various concentrations of resistin
(8.5, 12.5, 25, and 50 ng/ml) in different time-points (6 and 24 hours).
Experimental features Concentration-response and time-dependent optimization experiments to investigate the effect
of resistin on epithelial to mesenchymal transition (EMT) in breast cancer cells in vitro.
Data source location New York, USA, Friedman Diabetes Institute at Lenox Hill Hospital, Northwell Health
Data accessibility Raw data is provided
Related research article Avtanski D, Garcia A, Caraballo B, Thangeswaran P, Marin S, Bianco J, Lavi A, Poretsky L.
Resistin induces breast cancer cells epithelial to mesenchymal transition (EMT) and
stemness through both adenylyl cyclase-associated protein 1 (CAP1)-dependent and CAP1-
independent mechanisms. Cytokine. 2019 May; 120:155e64 [3].
Value of the data
 We demonstrated that resistin induces mRNA and protein expression of mesenchymal markers in MCF-7 and MDA-MB-
231 breast cancer cells, and inhibits epithelial markers expression in MCF-7 cells.
 We established optimal conditions for resistin treatment in human breast cancer cells in vitro as initial necessary step for
performing further experiments.
 Suppressor of cytokine signaling 3 (SOCS3) can be used as a control gene to evaluate the responsiveness of cancer cells to
resistin treatment.
 These data can be used to further strengthen our understanding of the role of obesity in cancer.
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1.2. Effect of resistin on the expression of epithelial to mesenchymal transition (EMT) markers in breast
cancer cells in vitro
Using similar treatment conditions, we evaluated the effect of resistin on the expression of various
mesenchymal and epithelial markers in MCF-7 and MDA-MB-231 cells. Results from qRT-PCR analysis
showed that in MDA-MB-231 cells, resistin significantly upregulated mRNA levels of key transcription
factors involved in EMT (SNAIL, SLUG, ZEB1, and TWIST1) as well as their target genes, fibronectin and
vimentin (Fig. 2 and Table 2). Results fromWestern blot analyses using MCF-7 and MDA-MB-231 cells
demonstrated that resistin significantly increased the protein expression levels of SNAIL and vimentin
in both MCF-7 and MDA-MB-231 cells, as well as concomitantly suppressed the protein levels of E-
cadherin and claudin-1 in MCF-7 cells ([3] and Table 3). In order to investigate EMT transcription factor
nuclear translocation events, we further performed fractionedWestern blot, analyzing ZEB1 and SNAIL
protein expression in separate cytoplasmic and nuclear fractions from MCF-7 and MDA-MB-231 cells
treated with resistin (12.5 ng/ml for 6 hours). The results from this experiment demonstrated that
resistin time-dependently induced the nuclear translocation of these two transcription factors in both,
MCF-7 and MDA-MB-231 cells ([3] and Table 4).
Fig. 1. Optimization of resistin treatment of MCF-7 and MDA-MB-231 cells. Concentration-response and time-dependent ex-
periments. MCF-7 (A) and MDA-MB-231 (B) cells were treated with various concentrations of resistin (8.3, 12.5, 25, and 50 ng/ml) for
6 and 24 hours. SOCS3 mRNA levels were measured by using qRT-PCR analysis. GAPDH was used as a housekeeping gene. Relative
mRNA levels and p values are listed in Table 1.
Table 1
Effect of resistin on SOCS3 mRNA levels in MCF-7 and MDA-MB-231 cells. Concentration-response and time-dependent
experiment using MCF-7 and MDA-MB-231 cells treated with resistin (8.3, 12.5, 25, and 50 ng/ml) for 6 and 24 hours. SOCS3
mRNA levels were measured by qRT-PCR analysis (see also Fig. 1). p values < 0.05 are shown in bold.
Treatment Time Cell Line MCF-7 MDA-MB-231
Concentration (ng/ml) mean ± SEM p Value mean ± SEM p Value
6h Control 1.047 ± 0.088 1.066 ± 0.107
8.3 1.542 ± 0.184 0.0248 1.706 ± 0.183 0.0053
12.5 1.829 ± 0.192 0.0002 2.187 ± 0.216 0.0001
25 1.277 ± 0.166 0.1864 1.430 ± 0.172 0.0752
50 1.016 ± 0.256 0.8854 1.182 ± 0.039 0.4322
24h Control 0.988 ± 0.112 1.017 ± 0.061
8.3 1.505 ± 0.194 0.0353 1.611 ± 0.136 0.0002
12.5 1.815 ± 0.231 0.0252 1.769 ± 0.185 0.0020
25 1.272 ± 0.162 0.2091 1.290 ± 0.124 0.0549
50 0.823 ± 0.139 0.4503 0.918 ± 0.104 0.4699
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2. Experimental design, materials and methods
2.1. Reagents
Human recombinant resistin (Cat. # PF-138) was purchased from Calbiochem® (EMD Millipore
Corp.). The lyophilized formwas reconstituted with water to a concentration of 100 mg/ml and further
to a series of dilutions of 8.3, 12.5, 25, and 50 mg/ml, which were used for cell treatment.
Fig. 2. Effect of resistin on mesenchymal gene expression in MDA-MB-231 cells. Quantitative RT-PCR analyses data on the relative
mRNA expression levels of SNAIL, SLUG, ZEB1, TWIST1, fibronectin and vimentin in MDA-MB-231 cells, untreated or treated with
resistin (12.5, 25, and 50 ng/ml for 6 and 24 hours). All fold-change data and p values are listed in Table 2.
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Table 2
Effect of resistin on mesenchymal gene expression in MDA-MB-231 cells. Concentration-response and time-dependent experiment for resistin treatment of MDA-MB-231 cells (see
Fig. 2). Cells were treated with various concentrations of resistin (12.5, 25 and 50 ng/ml) for 6 and 24 hours and relative mRNA levels of SNAIL, SLUG, ZEB1, TWIST1, fibronectin and vimentin
were measured by using qRT-PCR analysis. p values < 0.05 are shown in bold.
Resistin (ng/ml) 12.5 25 50 12.5 25 50
Treatment Time (h) 6 24
Gene Condition mean ± SEM p Value mean ± SEM p Value mean ± SEM p Value mean ± SEM p Value mean ± SEM p Value mean ± SEM p Value
SNAIL Control 1.015 ± 0.048 0.980 ± 0.079
Resistin 4.669 ± 0.721 0.0006 3.743 ± 0.823 0.0027 3.400 ± 0.549 <0.0001 1.922 ± 0.434 0.0398 2.271 ± 0.452 0.0020 2.457 ± 0.621 0.0040
SLUG Control 1.025 ± 0.043 0.933 ± 0.094
Resistin 1.921 ± 0.205 0.0019 2.282 ± 0.185 <0.0001 1.553 ± 0.315 0.0267 1.909 ± 0.404 0.0263 1.580 ± 0.124 0.0004 0.797 ± 0.147 0.4247
ZEB1 Control 1.002 ± 0.016 1.036 ± 0.060
Resistin 1.526 ± 0.119 0.0002 1.357 ± 0.042 <0.0001 1.096 ± 0.111 0.3641 1.318 ± 0.193 0.1813 1.223 ± 0.113 0.1220 0.748 ± 0.054 0.0014
TWIST1 Control 1.009 ± 0.035 1.088 ± 0.075
Resistin 3.335 ± 0.549 0.0008 1.500 ± 0.209 0.0108 1.201 ± 0.243 0.4293 2.901 ± 0.684 0.0245 1.427 ± 0.301 0.2253 1.219 ± 0.261 0.6319
Fibronectin Control 1.001 ± 0.025 1.034 ± 0.058
Resistin 1.742 ± 0.153 0.0074 1.573 ± 0.122 0.0093 0.947 ± 0.116 0.7563 1.420 ± 0.121 0.0362 1.191 ± 0.245 0.6319 0.492 ± 0.058 0.0003
Vimentin Control 1.125 ± 0.121
Resistin 3.241 ± 0.560 0.0006 2.050 ± 0.226 0.0014 1.607 ± 0.175 0.0289 2.658 ± 0.732 0.0337 1.201 ± 0.189 0.5287 1.044 ± 0.122 0.9197
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2.2. Cell lines and reagents
Human breast cancer MCF-7 and MDA-MB-231 cells were purchased from American Type Culture
Collection (ATCC) (Cat. ## HTB-22 and HTB-26, ATCC). Cells were grown in Dulbecco’s Modified Eagle’s
Medium (DMEM) (Cat. # 10-013-CF, Corning Inc.) supplemented with 10% FBS (Cat. # 1500-500, VWR
International) and 1x Antibiotic/Antimycotic Solution (Cat. # 30-004-CI, Corning, Inc.).
2.3. Quantitative RT-PCR analyses
Total RNA was extracted by using TRIzol™ reagent (Ambion, Thermo Fisher Scientific) and chlo-
roform, and precipitated with iso-propanol (VWR International). The precipitated RNA was washed
Table 3
Effect of resistin on epithelial and mesenchymal proteins expression in MCF-7 and MDA-MB-231 cells e densitometry
analysis.MCF-7 and MDA-MB-231 cells were treated with resistin (12.5 ng/ml) for 6 and 24 hours. Densitometry analyses were
performed using ImageJ software (NIH). Data are presented as % change of resistin treatment compared to control (no treatment)
after normalizing to GAPDH levels. p values < 0.05 are shown in bold.
Treatment Time 6h 24h
Protein Condition Protein Expression
(% ± SEM)
p Value Protein Expression
(% ± SEM)
p Value
MCF-7
SNAIL Control 100.00 ± 0.660
Resistin 195.90 ± 20.090 0.0002 236.10 ± 27.660 0.0002
Vimentin Control 100.00 ± 1.801
Resistin 147.10 ± 12.320 0.0016 262.70 ± 15.400 < 0.0001
E-cadherin Control 100.00 ± 9.933
Resistin 82.59 ± 6.082 0.2093 55.42 ± 6.600 0.0201
Claudin-1 Control 100.00 ± 12.460
Resistin 84.19 ± 9.331 0.3672 58.65 ± 4.992 0.0369
MDA-MB-231
SNAIL Control 100.00 ± 21.420
Resistin 249.80 ± 26.860 0.0005 235.80 ± 21.660 0.0004
Vimentin Control 100.00 ± 16.980
Resistin 201.00 ± 13.060 0.0002 170.70 ± 18.370 0.0122
Table 4
Effect of resistin on EMT-transcription factor nuclear translocation in MCF-7 and MDA-MB-231 cells e densitometry an-
alyses.MCF-7 and MDA-MB-231 cells were subjected to resistin treatment (12.5 ng/ml) for 6 and 24 hours. Western blots were
performed using separate (cytoplasmic and nuclear) protein fractions. b-Tubulin and lamin B1 were used as loading controls.
Densitometry analyses were performed using ImageJ software (NIH). Data are presented as % change of resistin treatment
compared to control (no treatment) after normalizing to the corresponding loading control. p values < 0.05 are shown in bold.
Protein Fraction Condition MCF-7 MDA-MB-231
Protein Expression
(% ± SEM)
p Value Protein Expression
(% ± SEM)
p Value
SNAIL Cytoplasmic Control 100.00 ± 13.380 96.67 ± 9.349
Resistin (12.5 ng/ml): 6h 55.09 ± 7.723 0.0438 58.63 ± 9.535 0.0465
Resistin (12.5 ng/ml): 24h 40.23 ± 14.720 0.0398 61.88 ± 4.449 0.0283
Nuclear Control 100.00 ± 4.044 100.00 ± 8.182
Resistin (12.5 ng/ml): 6h 218.500 ± 20.000 0.0044 158.10 ± 11.900 0.0159
Resistin (12.5 ng/ml): 24h 208.100 ± 9.646 0.0004 173.30 ± 13.670 0.0100
ZEB1 Cytoplasmic Control 98.100 ± 7.932 93.33 ± 4.913
Resistin (12.5 ng/ml): 6h 54.61 ± 8.793 0.0213 46.16 ± 10.970 0.0172
Resistin (12.5 ng/ml): 24h 46.39 ± 10.730 0.0179 37.42 ± 15.890 0.0283
Nuclear Control 100.00 ± 4.884 100.00 ± 13.350
Resistin (12.5 ng/ml): 6h 219.80 ± 6.828 0.0001 168.60 ± 15.550 0.0287
Resistin (12.5 ng/ml): 24h 255.50 ± 7.281 0.0179 191.70 ± 8.551 0.0044
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once with 70% ethanol, air-dried and resuspended in sterile, nuclease-free water, then the samples
were incubated at 65 C for 10 minutes and stored at 86 C until analyzed. Total RNA concentration
was determined using NanoDrop™ One Microvolume UVeVis Spectrophotometer (Thermo Fisher
Scientific), samples were normalized to 1 mg/ml RNA, and RT reaction was performed by using qScript
cDNA Synthesis Kit (Quanta Bio) and SimpliAmp thermal cycler (Applied Biosystems, Thermo Fisher
Scientific). Quantitative PCR analyses were performed by using PowerUp SYBR Green Master Mix and
QuantStudio 3 Real-Time PCR System (Applied Biosystems, Thermo Fisher Scientific). The following
primer sequences (50-30) were used: SOCS3, (forward) CCTGCGCCTCAAGACCTTC, (reverse)
GTCACTGCGCTCCAGTAGAA (PrimerBank ID 45439351c1); SNAIL, (forward) AAGATGCA-
CATCCGAAGCCA, (reverse) CAAAAACCCACGCAGACAGG [5]; SLUG, (forward) CTTCCTGGTCAAGAAGCA
(reverse), GGGAAATAATCACTGTATGTGTG [6]; ZEB1, (forward) GCACAACCAAGTGCAGAAGA, (reverse)
GCCTGGTTCAGGAGAAGATG [7]; TWIST1, (forward) GGCTCAGCTACGCCTTCTC, (reverse) CTAGTGG-
GACGCGGACAT [8]; fibronectin, (forward) ATGATGAGGTGCACGTGTGT, (reverse) CTCTGAATCCTGG-
CATTGGT [7]; vimentin, (forward) AGATGGCCCTTGACATTGAG, (reverse) TGGAAGAGGCAGAGAAATCC
[7]; GAPDH, (forward) CCTGCACCACCAACTGCTTA, (reverse) GGCCATCCACAGTCTTCTGAG [9]. The
annealing temperature for all of the PCR analyses was 60 C.
2.4. Western blot analyses
Whole cellular protein was extracted by using Pierce™ RIPA Lysis Buffer (Cat. # 89901, Thermo
Fisher Scientific) supplemented with protease inhibitor cocktail (Mammalian ProteaseArrest, Cat. #
786-331, G-Biosciences) and phosphatase inhibitors (PhosphataseArrest™, Cat. # 786-450, G-Bio-
sciences). Cytoplasmic and nuclear protein fractures were extracted by using Nuclear & Cytoplasmic
Extraction Kit (G Biosciences®, Cat. # 786-182) following manufacturer’s protocol. Protein concen-
trations were quantified by using Pierce™ BCA Protein Assay Kit (Cat. # 23225, Thermo Fisher Sci-
entific), BioTek® plate reader and Gen5™ data analysis software (BioTek®). Protein extracts were
separated by polyacrylamide gel electrophoresis (SDS-PAGE), and transferred onto nitrocellulose
membranes (Amersham, GE Healthcare). Membranes were blotted with SNAIL (C15D3) Rabbit mAb
(Cat. # 3879), SLUG (C19G7) Rabbit mAb (Cat. # 9585), TCF8/ZEB1 (D80D3) Rabbit mAb (Cat. # 3396),
Vimentin (D21H3) XP Rabbit mAb (Cat. # 5741), E-cadherin (24E10) Rabbit mAb (Cat. # 3195), Claudin-
1 (D5H1D) XP Rabbit mAb (Cat. # 13255), GAPDH (14C10) Rabbit mAb (Cat. # 2118) (Cell Signaling
Technology), b Tubulin (D-10) mAb (Cat. # sc-5274), and Lamin B1 (B-10) mAb (Cat. # sc-374015) (Santa
Cruz Biotechnology) primary antibodies and Pierce™ Goat Anti-Rabbit Horseradish Peroxidase Con-
jugated Secondary Antibody (Cat. # 31460, Thermo Fisher Scientific). Protein bands were visualized by
using SuperSignal West Pico Chemiluminescent Substrate (Cat. # 34580, Cell Signaling Technology)
and MyECL™ Imager (Thermo Fisher Scientific). Densitometry analyses were performed with ImageJ
software (National Institutes of Health) and protein expression levels were presented as percentage
difference compared to control (±SEM).
2.5. Statistical analyses
Quantitative RT-PCR analyses data were based on 4-6 separate experiments, as each experimental
conditionwas set up in duplicates, and each sample was analyzed in duplicates. Densitometry analysis
of the Western blot data was based on 3 different experiments. Statistical analysis were carried out
using GraphPad Prism 7 software (GraphPad Software, La Jolla, CA). Data were analyzed using ANOVA.
Results are expressed as mean ± SEM and are considered statistically significant if p < 0.05.
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